Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicamtiv PK with Itraconazole or Diltiazem
NCT05162222Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of danicamtiv in dilated cardiomyopathy (DCM) and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 17 days, Area under the plasma concentration-time curve extrapolated to infinite time up to 17 days and 1 more. Started Dec 2021; status: completed.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05162222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162222.